Getting this right can protect your health
Chromium helps improve insulin sensitivity and affects carbohydrate, protein, and lipid metabolism [3]
Tirzepatide (Mounjaro, Zepbound) is a related but distinct medication that acts as a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist
doi: 10.1111/ijd.13303
Walker et al., 2010), mitochondrial associated membrane (MAM) dysfunction (Watanabe et al., 2016), ER-Golgi transport defects (Atkin et al., 2014

Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months